Vitamin D deficiency is associated with inferior survival of patients with extranodal natural killer/T-cell lymphoma

Seok Jin Kim1,2 | Cheng Shu3 | Kyung Ju Ryu2 | Danbee Kang4,5
Juhee Cho4,5,6 | Young Hyeh Ko7 | Soo-Youn Lee8 | Eliseo Guallar4,6
Weili Zhao3 | Won Seog Kim1

1Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
2Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea
3State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
4Center for Clinical Epidemiology, Samsung Medical Center, Seoul, Korea
5Department of Clinical Research Design and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea
6Department of Epidemiology, Epidemiology and Clinical Research, Johns Hopkins Medical Institutions, Baltimore, MD, USA
7Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
8Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Correspondence
Won Seog Kim, Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Email: wskimsmc@skku.edu

Funding Information
National Research Foundation of Korea, Grant/Award Number: NRF-2017R1A2B4005136

Vitamin D deficiency is a common health issue; however, the effect of vitamin D deficiency on the survival of T-cell lymphoma is still not clear. We evaluated the impact of serum vitamin D level of patients with peripheral T-cell lymphoma (PTCL) and extranodal natural killer/T-cell lymphoma (ENKTL) on survival outcome. Pretreatment levels of 25-hydroxyvitamin D [25(OH)D] and inflammatory cytokines were measured in serum samples that were archived at diagnosis, and we evaluated their association with survival in newly diagnosed patients with PTCL (n = 137) and ENKTL (n = 114) at a university-based hospital in Korea. An independent cohort from Rui Jin Hospital (Shanghai, China) was used for validation. The median 25(OH)D serum level was 12.0 ng/mL (1.3–60.0 ng/mL), and 40% had less than 10 ng/mL, which was defined as vitamin D deficiency. Median serum 25(OH)D levels were similar between PTCL (11.5 ng/mL) and ENKTL (12.9 ng/mL); however, vitamin D deficiency was associated with inferior survival in ENKTL but not with PTCL. The independent validation cohort (n = 115) also showed a significant association of vitamin D deficiency with poor survival in ENKTL. The 25(OH)D level had an inverse relation with inflammatory cytokines; this association had a negative effect only on survival of ENKTL, and not on PTCL. In conclusion, vitamin D deficiency was associated with inferior survival outcome of patients with ENKTL.

KEYWORDS
chemotherapy, NK/T-cell lymphoma, prognosis, survival, vitamin D
Vitamin D deficiency is highly prevalent in the general population. Low sun exposure and oral intake are the main reasons for vitamin D deficiency. Beside its main effect on bone metabolism, vitamin D deficiency is a risk factor for cancer development as well as poor treatment outcome. In non-Hodgkin lymphoma (NHL) patients, the prognostic value of vitamin D deficiency has increased interest since a previous cohort study with newly diagnosed NHL patients reported the negative effect of vitamin D deficiency on prognosis. Recently, 2 prospective cohort studies demonstrated an association of vitamin D deficiency with survival outcome of patients with diffuse large B-cell lymphoma and follicular lymphoma who received rituximab-containing chemotherapy. Studies have suggested that vitamin D deficiency might impair rituximab-mediated cytotoxicity, leading to an inferior outcome for patients. Yet, there are few data on the association of vitamin D deficiency with the prognosis of T-cell and natural killer (NK)-cell lymphoma. To date, only 1 study has reported the negative effect of vitamin D deficiency on the survival of T-cell lymphoma. However, the study analyzed a relatively small number of T-cell lymphomas and information about NK/T-cell lymphoma was lacking. Because the main treatment for T-cell and NK-cell lymphomas does not include monoclonal antibodies unlike B-cell lymphomas, the effect of vitamin D deficiency on the survival outcome of these disease entities and underlying mechanisms might be different from that of B-cell lymphomas.

Thus, the present study aims to investigate the role of vitamin D in patients with peripheral T-cell lymphoma (PTCL) and extranodal NK/T-cell lymphoma, nasal type (ENKTL). We hypothesized that PTCL and ENKTL patients with vitamin D deficiency would have inferior survival outcomes because vitamin D deficiency is associated with the risk of mortality in the general population as well as cancer patients. Therefore, we evaluated the association of survival outcome with vitamin D deficiency in a prospective cohort of consecutively enrolled Korean patients with newly diagnosed PTCL and ENKTL and validated our results in an independent Chinese cohort. Vitamin D deficiency was based on measuring the serum level of 25-hydroxyvitamin D [25(OH)D] because 25(OH)D is currently considered the biomarker that most accurately reflects the storage form of vitamin D. In the present study, we defined a serum level of 25(OH)D < 10 ng/mL as vitamin D deficiency because the global definition of vitamin D deficiency has commonly been serum 25(OH)D < 10 ng/mL.

Peripheral T-cell lymphoma and ENKTL were separately analyzed because the current chemotherapy regimens for ENKTL are nonanthracycline-based and L-asparaginase-containing chemotherapies. We also analyzed the correlation of serum levels of inflammatory cytokines with 25(OH)D to elucidate the association of vitamin D deficiency with survival outcome in PTCL and ENKTL given the pro-inflammatory effect of vitamin D deficiency.

2 | PATIENTS AND METHODS

2.1 | Study design

Patients in the discovery cohort were participants enrolled in 2 prospective cohort studies: Samsung Medical Center-Lymphoma Cohort Studies I (2008-2011, NCT#00822731) and II (2012-2016, NCT#01877109). From May 1 to September 31, 2013, they conducted a multicenter study on 2173 apparently healthy adults who were recruited from 5 Chinese cities: Dalian, Beijing, Hangzhou, Guangzhou, and Urumqi. From these cohort studies, following provision of written informed consent, we gathered clinical and laboratory characteristics, including age, performance status, B symptoms, Ann Arbor stage and serum lactate dehydrogenase (LDH). We also collected pretreatment serum samples at diagnosis and stored them at -80°C until analysis. The Institutional Review Board at the Samsung Medical Center reviewed and approved all aspects of the study. For the establishment of the discovery cohort for this analysis, we selected 251 patients with PTCL or ENKTL according to the following inclusion criteria: (i) newly diagnosed patients with PTCL and ENKTL; (ii) patients receiving treatment with curative intent; and (iii) patients having archived frozen serum samples available for the measurement of vitamin D and cytokine assay (Figure 1A). Cutaneous T-cell lymphomas were excluded from the study cohort because of their indolent nature. A review of pathology data was performed by an expert on lymphoma pathology (K.Y.H) according to the 2008 World Health Organization classification criteria. Serum levels of 25(OH) D were measured in the aforementioned archived serum samples, and their association with survival outcomes was analyzed. The last update of survival and disease status for this analysis was done in May 2017. To validate the findings of the study, we used data obtained from the registry of the Shanghai Rui Jin Hospital. In total, 115 patients with PTCL or ENKTL were treated with curative intent between June 2013 and February 2017; their serum level of 25(OH) D was measured at diagnosis during the initial work-up (Figure 1B). The pathologist of the Shanghai Rui Jin Hospital undertook the pathology review and final diagnosis of PTCL and ENKTL.

2.2 | Serum vitamin D measurement

All archived samples of the discovery cohort were sent to the Department of Laboratory Medicine at the Samsung Medical Center, and vitamin D levels were determined from a single baseline serum sample. Serum levels of 25(OH)D2 and D3 were determined by high-performance liquid chromatography-tandem mass spectrometry, with an Agilent 6460 Triple Quad mass spectrometer equipped with a 1200 liquid chromatography system (Agilent Technologies, Waldbronn, Germany). The intra-assay and inter-assay imprecisions were <10% of coefficients of variation, and the combination of 25(OH)D2 and D3 < 10 ng/mL was defined as vitamin D deficiency. Although various cutoff values for vitamin D deficiency have been used in previous studies, such as 20 ng/mL of 25(OH)D for follicular lymphoma and 8 ng/mL of 25(OH)D3 for diffuse large B-cell lymphoma, we used a cutoff of 10 ng/mL given the high prevalence of
vitamin deficiency in the Asian population. In the validation cohort, the serum level of 25(OH)D was measured at the Shanghai Rui Jin Hospital laboratory, and the same cutoff value (10 ng/mL) was used.

2.3 | Measurement of serum cytokines

We performed multiplexed assays for the measurement of cytokines using archived serum samples of the discovery cohort to analyze their association with serum vitamin D levels. We used the Procarta cytokine profiling kit (Human ProcartaPlex; Panomics, San Diego, CA, USA) to detect and quantify the following 34 protein targets simultaneously: eotaxin, GM-CSF, GROα, IFNα, IFNγ, IL-1α, IL-1β, IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-15, IL-17A, IL-17F, IL-21, IL-22, IL-31, IP-10, MCP-1, MIP-1α, MIP-1β, RANTES, SDF1α, TNFα and TNFβ. All measurements were performed in duplicate according to the manufacturer’s instructions.

2.4 | Statistics

The association of serum vitamin D with categorical variables was analyzed using the χ²-test. The Kaplan-Meier method and log-rank test were used to assess the association of vitamin D deficiency and survival. Progression-free survival (PFS) was measured from the date of diagnosis to the date of death from any cause or date of disease progression or relapse, and overall survival (OS) was from the date of diagnosis to the date of death from any cause. Patients without an event or death were censored at the date of the last follow-up visit. THE Cox proportional hazard regression model was used to calculate the hazard ratio of PFS adjusting for prognostic factors, including age, performance status, Ann Arbor stage and serum LDH. All statistical analyses were performed using the software package IBM PASW (version 23.0; SPSS, Chicago, IL, USA) and a 2-sided P-value <0.05 was considered significant.

3 | RESULTS

3.1 | Patients

The discovery cohort consisted of patients who were consecutively diagnosed with PTCL (n = 137) and ENKTL (n = 114) between September 2008 and June 2016 at the Samsung Medical Center. The median age of PTCL and ENKTL patients was 57 years (range: 18-85 years) and 53 years (range: 17-78 years),
|                                | Extranodal NK/T-cell lymphoma | Peripheral T-cell lymphoma |
|--------------------------------|--------------------------------|----------------------------|
|                                | Discovery cohort (n = 114) | Validation cohort (n = 61) | Discovery cohort (n = 137) | Validation cohort (n = 54) |
| Age (y)                        |                                |                            |                            |                            |
| ≤60                            | 85 (75%)                       | 48 (79%)                   | 83 (61%)                    | 39 (72%)                    |
| >60                            | 29 (25%)                       | 13 (21%)                   | 54 (39%)                    | 15 (28%)                    |
| Sex                            |                                |                            |                            |                            |
| Male                           | 80 (70%)                       | 43 (70%)                   | 91 (66%)                    | 37 (69%)                    |
| Female                         | 34 (30%)                       | 18 (30%)                   | 46 (34%)                    | 17 (31%)                    |
| ECOG performance status        |                                |                            |                            |                            |
| 0/1                            | 99 (87%)                       | 57 (93%)                   | 115 (84%)                   | 48 (89%)                    |
| ≥2                             | 15 (13%)                       | 4 (7%)                     | 22 (16%)                    | 6 (11%)                     |
| Stage                          |                                |                            |                            |                            |
| I/II                           | 72 (63%)                       | 42 (69%)                   | 33 (24%)                    | 4 (7%)                      |
| III/IV                         | 42 (37%)                       | 19 (31%)                   | 104 (76%)                   | 50 (93%)                    |
| Serum LDH                      |                                |                            |                            |                            |
| Normal                         | 61 (54%)                       | 37 (61%)                   | 59 (43%)                    | 26 (48%)                    |
| Increased                      | 53 (46%)                       | 24 (39%)                   | 78 (57%)                    | 28 (52%)                    |
| Bone marrow involvement        |                                |                            |                            |                            |
| Absence                        | 89 (78%)                       | 46 (75%)                   | 97 (71%)                    | 39 (72%)                    |
| Presence                       | 25 (22%)                       | 15 (25%)                   | 40 (29%)                    | 15 (28%)                    |
| Number of extranodal involvement |                             |                            |                            |                            |
| 0/1                            | 65 (57%)                       | 50 (82%)                   | 83 (61%)                    | 49 (91%)                    |
| ≥2                             | 49 (43%)                       | 11 (18%)                   | 54 (39%)                    | 5 (9%)                      |
| B symptoms                     |                                |                            |                            |                            |
| Absence                        | 72 (63%)                       | NA                         | 85 (62%)                    | NA                          |
| Presence                       | 42 (37%)                       | NA                         | 52 (38%)                    | NA                          |
| International prognostic index |                                |                            |                            |                            |
| Low/low-intermediate           | 78 (68%)                       | 54 (89%)                   | 72 (53%)                    | 33 (61%)                    |
| High-intermediate/high         | 36 (32%)                       | 7 (11%)                    | 65 (47%)                    | 24 (39%)                    |
| 1st line treatment             |                                |                            |                            |                            |
| CHOP/CHOP-like                 | 127 (93%)                      |                            |                            | 54 (100%)                   |
| CCRT +/- chemotherapy          | 60 (53%)                       |                            |                            |                            |
| L-asparaginase containing chemotherapy | 45 (39%) | 60 (98%)                   |                            |                            |
| Other chemotherapy             | 9 (8%)                         | 1 (2%)                     | 10 (7%)                     |                            |
| Response to 1st line treatment |                                |                            |                            |                            |
| Complete response              | 75 (66%)                       | 40 (66%)                   | 84 (61%)                    | 16 (30%)                    |
| Partial response               | 8 (7%)                         | 8 (13%)                    | 20 (15%)                    | 19 (35%)                    |
| Progressive disease            | 30 (26%)                       | 8 (13%)                    | 27 (20%)                    | 13 (24%)                    |
| Not evaluated                  | 1 (1%)                         | 5 (8%)                     | 6 (4%)                      | 6 (11%)                     |
| Subtype                        |                                |                            |                            |                            |
| PTCL-NOS/AITL                  | 55/44 (72%)                    |                            | 29/16 (83%)                 |                            |
| ALCL-ALK−/ALK+                 | 25/5 (22%)                     |                            | 3/5 (15%)                   |                            |
| Others                         | 8 (6%)                         |                            | 1 (2%)                      |                            |

AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large cell lymphoma; CCRT, concurrent chemoradiotherapy; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; NA, not available; PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified.
respectively. Most PTCL patients (n = 127) were treated with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or CHOP-like regimens regardless of stage (Table 1). However, stage I/II ENKTL patients were mainly treated with concurrent chemoradiotherapy followed by systemic chemotherapy (n = 60). Remaining stage I/II and III/IV patients received chemotherapy alone (n = 54), and most systemic chemotherapies were based on non-anthracycline and L-asparaginase-containing regimens.13-15 Other chemotherapy regimens did not include L-asparaginase such as etoposide, ifosfamide, cisplatin and dexamethasone.16 The validation cohort consisted of patients who were diagnosed with PTCL (n = 54) and ENKTL (n = 61) between September 2013 and February 2017 at the Shanghai Rui Jin Hospital. The median age of PTCL and ENKTL patients was 57 years (range: 20-75 years) and 44 years (range: 14-72 years), respectively. Like the discovery cohort, most PTCL patients received CHOP or CHOP-like treatment (Table 1). The main treatment for ENKTL patients was based on non-anthracycline and PEGylated L-asparaginase-containing chemotherapy regimens.17 Vitamin D supplementation was not given to all patients during treatment in the discovery and validation cohort.

### 3.2 | Vitamin D deficiency

The median 25(OH)D serum level of the discovery cohort (n = 251) was 12.0 ng/mL, with a range of 1.3-60.0 ng/mL. One hundred and five patients (42%) of the discovery cohort had below 10 ng/mL of 25(OH)D at diagnosis, whereas 146 patients (58%) had 25(OH)D ≥ 10 ng/mL. The distribution of serum 25(OH)D was similar between PTCL (median: 11.3 ng/mL; range: 1.3-60.0 ng/mL) and ENKTL (median: 12.5 ng/mL; range: 1.6-57.4 ng/mL) patients (Figure 1C). As 25(OH)D was measured from serum samples archived immediately after diagnosis in the discovery cohort, the serum level of 25(OH)D could represent the amount of vitamin D in each patient. Median serum calcium level was also similar between PTCL (median: 8.9 mg/dL; range: 6.5-13.8 mg/dL) and ENKTL (median: 8.9 mg/dL; range: 6.6-10.2 mg/dL) patients. Serum calcium levels were positively correlated with serum levels of 25(OH)D in PTCL (r = .436, P < .001) and ENKTL (r = .294, P = .002) patients. The median 25(OH)D serum level of the validation cohort (n = 115) was 13.1 ng/mL (range: 3.0-35.0 ng/mL), and it was higher than that of the discovery cohort. Thus, 37 patients (32%) had vitamin D deficiency at diagnosis, whereas 78 patients (68%) had 25(OH)D ≥ 10 ng/mL. However, the distribution of serum 25(OH)D was similar between PTCL (median: 11.5 ng/mL; range: 3.0-30.4 ng/mL) and ENKTL (median: 14.1 ng/mL; range: 3.0-35.0 ng/mL) patients (Figure 1D). Vitamin D deficiency was significantly associated with advanced disease and unfavorable parameters such as serum LDH and poor performance status in the discovery cohort (P < .05; Table 2). Accordingly, the response to the first-line treatment was significantly associated with vitamin D deficiency in ENKTL (P < .05; Table 2). Although the association between response and vitamin D deficiency was also significant in PTCL, the statistical value was less than that of ENKTL.

### 3.3 | Association of vitamin D deficiency with survival

The estimated median follow-up time of the discovery and validation cohort was 35.8 months (95% confidence interval [CI]: 29.4-42.2 months) and 15.0 months (95% CI: 12.0-18.0 months), respectively. In the discovery cohort, 102 patients died at the time of analysis, and the cause of death was as follows: disease progression (n = 72), treatment-related mortality (n = 18) and other causes including accidents (n = 10). The PFS and OS were significantly worse in ENKTL patients with vitamin D deficiency, whereas vitamin D deficiency failed to show a significant association with PFS and OS in PTCL patients (Figures 2A,B and S1). The PFS of ENKTL was also different in patients treated with concurrent chemoradiotherapy followed by chemotherapy and patients who received just chemotherapy alone, although it was not statistically significant due to a relatively low number of patients (Figure S2). The survival analysis using the validation cohort showed the same association of vitamin D deficiency with survival outcomes in ENKTL patients but not in PTCL patients (Figures 2C,D and S1). Multivariate analysis with unfavorable parameters, including vitamin D deficiency of the discovery cohort, showed that the vitamin D deficiency was independently associated with poor PFS (P < .05; Table 3).

### 3.4 | Association of vitamin D deficiency with inflammatory cytokines

Sixteen cytokines (IL-6, IL-8, IL-10, IL-18, IL-23, TNFα, MCP-1, MIP-1α, MIP-1β, RANTES, Eotaxin, GROα, IFNα, IFNγ, IP-10 and SDF1α) were examined because the levels of the other cytokines were too low to be analyzed. The mean value of inflammatory cytokines was significantly higher in patients with vitamin D deficiency than in patients without it (Figure 3A,B). However, the association of inflammatory cytokines with survival was different between ENKTL and PTCL. Thus, when patients were dichotomized into high and low groups according to the median value, high inflammatory cytokines were significantly associated with survival outcome only in ENKTL, and not in PTCL (Figure S3).

### 4 | DISCUSSION

Vitamin D is one of the most commonly deficient vitamins worldwide and a low level of vitamin D is more common in Asian countries to Western countries.18,19 Thus, the National Health and Nutrition Examination Survey (NHNES) in the Korean population that was conducted in 2008 reported 56.9% of Korean people had serum 25(OH)D level below 20 ng/mL, and the multicenter study on 2173 healthy adults in five Chinese cities (Dalian, Beijing, Hangzhou, Guangzhou, and Urumqi) that was conducted in 2013 also showed 55.9% of people had serum 25(OH)D level below 20 ng/mL.20,21 These results were higher than 32% of the NHNES in the United States.22 Two Asian studies suggested behavioral changes, including increased
| Characteristics | Extranodal NK/T-cell lymphoma | Peripheral T-cell lymphoma |
|-----------------|-----------------------------|---------------------------|
|                 | Serum 25(OH)D (ng/mL)        | Serum 25(OH)D (ng/mL)     |
|                 | <10 (n = 44)                | ≥10 (n = 70)              |
| Age (y)         | P                           | P                         |
| ≤60             | 34                          | 41                        |
| >60             | 10                          | 42                        |
| Sex             |                             |                           |
| M               | 28                          | 39                        |
| F               | 16                          | 52                        |
| ECOG PS         |                             |                           |
| 0/1             | 33                          | 45                        |
| ≥2              | 11                          | 16                        |
| Stage           |                             |                           |
| I/II            | 19                          | 8                         |
| III/IV          | 25                          | 25                        |
| Serum LDH       |                             |                           |
| Normal          | 16                          | 18                        |
| Increased       | 28                          | 43                        |
| BM              |                             |                           |
| Not involved    | 28                          | 40                        |
| Involved        | 16                          | 21                        |
| Number of EN    |                             |                           |
| 0/1             | 19                          | 32                        |
| ≥2              | 25                          | 29                        |
| B Symptoms      |                             |                           |
| Absence         | 21                          | 28                        |
| Presence        | 23                          | 33                        |
| IPI             |                             |                           |
| L/LI            | 22                          | 30                        |
| HI/H            | 22                          | 31                        |
| 1st treatment   |                             |                           |
| L-asparaginase CTx | 27                        | 18                        |
| CCRT + CTx     | 13                          | 47                        |
| CHOP/CHOP-like  |                             | 56                        |
| Others          | 4                           | 5                         |
| Response        |                             |                           |
| CR              | 18                          | 33                        |
| PR              | 4                           | 9                         |
| PD              | 22                          | 11                        |
| NE              | 0                           | 6                         |
| Subtype         |                             |                           |
| PTCL-NOS        | 19                          | 36                        |
| AITL            | 24                          | 20                        |
| ALCL-ALK −/+    | 14                          | 16                        |
| Others          | 4                           | 4                         |

25(OH)D, 25-hydroxyvitamin D; AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large cell lymphoma; BM, Bone marrow; BMI, body mass index; CCRT, concurrent chemoradiotherapy; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; CR, complete response; CTx, chemotherapy; ECOG, Eastern Cooperative Oncology Group; H, high; HI, high-intermediate; IPI, International Prognostic Index; L, low; LDH, lactate dehydrogenase; LI, low-intermediate; NE, not evaluated; No. of EN, Number of extranodal involvement; PD, progressive disease; PR, partial response; PS, performance status; PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified.
indoor lifestyle and sunscreen use, as possible factors for their high prevalence. A low level of 25(OH)D was more frequent in cancer patients, and vitamin D deficiency was associated with poor outcome like its proven negative effect in general population.2 Our study also showed a high frequency of vitamin D deficiency in Korean and Chinese patients with PTCL and ENKTL at diagnosis, and this might support 2 cohort studies reporting that vitamin D deficiency itself could increase the risk of lymphoma.23,24 In other words, patients with PTCL and ENKTL might have vitamin D deficiency at diagnosis because people who have vitamin D deficiency were at a higher risk of developing PTCL and ENKTL. In contrast, the negative effect of lymphoma on general health status leading to impaired outdoor activity and poor oral intake might increase the frequency of vitamin D deficiency in patients with PTCL and ENKTL. Indeed, unfavorable parameters reflecting tumor burden, such as stage and serum LDH, as well as poor performance status, were significantly related to vitamin D deficiency in the study cohort (Table 2). However, it is also possible that patients with a larger tumor burden might have artificially low serum 25(OH)D levels because they may have increased conversion of 25(OH)D to 1,25(OH)2D due to increased 1α-hydroxylase activity from the tumor.

In this study, ENKTL patients with vitamin D deficiency had inferior PFS and OS to patients without it, whereas the PFS and OS were not significantly different in PTCL patients. The analysis of PFS and OS using the validation cohort also showed the same pattern of association even though the median follow-up of the validation cohort (15.0 months) was relatively shorter than that of the discovery cohort (35.8 months, Figure 1). This negative effect

**FIGURE 2** A, B, The comparison of progression-free survival according to serum 25(OH)D levels (<10 ng/mL vs ≥10 ng/mL) show a significant difference in patients with extranodal natural killer/T-cell lymphoma compared with peripheral T-cell lymphoma of the discovery cohort. C, D, The progression-free survival of the validation cohort shows the same pattern as the study cohort.
of vitamin D deficiency on survival of ENKTL patients might be related to the peculiar characteristics of ENKTL. Tumor cells of ENKTL were invariably infected with Epstein-Barr virus and inflammatory milieu surrounding tumor cells might influence the tumor aggressiveness of ENKTL. Indeed, increased inflammatory cytokines in the tumor microenvironment were associated with poor treatment outcome of ENKTL. Vitamin D deficiency was reported to influence the tumor microenvironment, facilitating tumor outgrowth by impairing the immune system. Thus, the association of survival with vitamin D deficiency in ENKTL patients could be explained by the contributory effect of vitamin D deficiency on the inflammatory microenvironment. In this study, pretreatment serum inflammatory cytokines were inversely associated with serum levels of 25(OH)D (Figure 3). Therefore, patients

| Characteristics                     | Univariate | Multivariate |
|-------------------------------------|------------|--------------|
|                                     | P         | Hazard ratio | 95% confidence interval | P   |
| Age > 60 y                          | .020      | 2.008        | 1.128                    | 3.575 | .018 |
| ECOG PS ≥2                         | <.001     | 1.631        | .776                     | 3.428 | .197 |
| Stage III/IV                        | <.001     | 1.557        | .652                     | 3.719 | .319 |
| Increased serum LDH                | <.001     | 1.204        | .626                     | 2.313 | .578 |
| Extramedial involvement ≥2         | .011      | .931         | .469                     | 1.848 | .838 |
| Bone marrow involvement             | <.001     | 2.097        | .959                     | 4.587 | .064 |
| Serum 25(OH)D < 10 ng/mL           | <.001     | 1.888        | 1.065                    | 3.347 | .030 |

ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; PS, performance status; Serum 25(OH)D, 25-hydroxyvitamin D.

**FIGURE 3** A, B, Comparison of mean values of cytokines in peripheral T-cell lymphoma and extramedial natural killer/T-cell lymphoma of the discovery cohort
with vitamin D deficiency had increased levels of inflammatory cytokines in accordance with previous reports. The PFS of patients with increased levels of those inflammatory cytokines was worse than that of patients without them in ENKTL. However, this association between inflammatory cytokines and PFS was not evident in PTCL (Figure S3).

Vitamin D is implicated in immune function and inflammation, and vitamin D was found to inhibit the gene expression of proinflammatory cytokines, including interleukins and TNFα. Given the prognostic value of these inflammatory cytokines in ENKTL, patients with a vitamin D deficiency might have a poor prognosis due to subsequent elevated levels of cytokines. Although inflammatory cytokines might influence the aggressiveness of PTCL, their contribution to a worse outcome with PTCL might be less than that of ENKTL. Further study with a larger sample is necessary to confirm the results of this finding. The different impact of vitamin D deficiency on PFS in PTCL and ENKTL might be associated with a greater heterogeneity in PTCL than in ENKTL. In our study, PTCL includes several subtypes, such as PTCL-NOS and AITL, whereas ENKTL is a homogeneous disease entity. Indeed, the impact of vitamin D deficiency on PFS was different among PTCL subtypes. The PFS of PTCL-NOS was not associated with vitamin D deficiency, whereas the PFS of AITL showed a modest association, although it failed to show a statistical significance owing to relatively small numbers (data not shown). Considering that various single parameters related with immune function and inflammation, such as ferritin, have been reported to have prognostic value in PTCL, the role of vitamin D deficiency in the prognosis of PTCL needs to be further studied with a larger study population.

Given the high prevalence of vitamin D deficiency in Asian countries and the negative impact of vitamin D deficiency on the survival of ENKTL patients, vitamin D supplementation might have a positive effect on Asian patients’ survival outcome because ENKTL is a more common subtype of NHL in East Asian countries than Western countries. However, it is still not clear whether vitamin D replacement has an impact on prognosis in lymphoma patients. An ongoing clinical trial with vitamin D replacement for patients with lymphoid malignancies may provide evidence for the role of vitamin D (#NCT01787409). Indeed, a recent interim report from the trial showed that vitamin D replacement therapy could achieve target levels of 25(OH)D of 30 ng/mL at 12 weeks without toxicity.

In conclusion, our study demonstrated that vitamin D deficiency might be associated with inferior survival outcome of patients with ENKTL but not with PTCL. Further investigations with larger study populations and longer median follow-up than our study are needed to confirm our findings and to determine the effects of vitamin D supplementation in patients with PTCL and ENKTL on survival.

ACKNOWLEDGMENTS

We thank all our colleagues who participated in the research and express our gratitude to the 20-20 project of the Samsung Medical Center.

CONFLICT OF INTEREST

The authors have no conflict of interests to report.

ORCID

Seok Jin Kim http://orcid.org/0000-0002-2776-4401

REFERENCES

1. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266-281.
2. Li M, Chen P, Li J, Chu R, Xie D, Wang H. Review: the impacts of circulating 25-hydroxyvitamin D levels on cancer patient outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2014;99:2327-2336.
3. Drake MT, Maurer MJ, Link BK, et al. Vitamin D insufficiency and prognosis in non-Hodgkin’s lymphoma. J Clin Oncol. 2010;28:4191-4198.
4. Bittenbring JT, Neumann F, Altmann B, et al. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. J Clin Oncol. 2014;32:3242-3248.
5. Kelly JL, Salles G, Goldman B, et al. Low serum vitamin D levels are associated with inferior survival in follicular lymphoma: a prospective evaluation in SWOG and LYSA studies. J Clin Oncol. 2015;33:1482-1490.
6. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008;168:1629-1637.
7. Zerwekh JE. Blood biomarkers of vitamin D status. Am J Clin Nutr. 2008;87:1087S-1091S.
8. Lips P. Which circulating level of 25-hydroxyvitamin D is appropriate? J Steroid Biochem Mol Biol. 2004;89-90:611-614.
9. Tse E, Kwong YL. The diagnosis and management of NK/T-cell lymphomas. J Hematol Oncol. 2017;10:85.
10. Aranow C. Vitamin D and the immune system. J Invest Med. 2011;59:881-886.
11. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.
12. Choi R, Kim S, Yoo H, et al. High prevalence of vitamin D deficiency in pregnant Korean women: the first trimester and the winter season as risk factors for vitamin D deficiency. Nutrients. 2015;7:3437-3448.
13. Kwong YL, Kim WS, Lim ST, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012;120:2973-2980.
14. Kim SJ, Yang DH, Kim JS, et al. Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T-cell lymphoma: CISL08-01 phase II study. Ann Hematol. 2014;93:1895-1901.
15. Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011;29:4410-4416.
16. Kim SJ, Kim K, Kim BS, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol. 2009;27:6027-6032.
17. Liang R, Gao GX, Chen JP, et al. A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for...
newly diagnosed, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial in Northwest China. Hematol Oncol. 2016;35:619-629.

18. Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr. 2008;87:1080S-1086S.

19. Hilger J, Friedel A, Herr R, et al. A systematic review of vitamin D status in populations worldwide. Br J Nutr. 2014;111:23-45.

20. Choi HS, Oh HJ, Choi H, et al. Vitamin D insufficiency in Korea—a greater threat to younger generation: the Korea National Health and Nutrition Examination Survey (KNHANES) 2008. J Clin Endocrinol Metab. 2011;96:643-651.

21. Yu S, Fang H, Han J, et al. The high prevalence of hypovitaminosis D in China: a multicenter vitamin D status survey. Medicine (Baltimore). 2015;94:e585.

22. Ganji V, Zhang X, Tangpricha V. Serum 25-hydroxyvitamin D concentrations and prevalence estimates of hypovitaminosis D in the U.S. population based on assay-adjusted data. J Nutr. 2012;142:498-507.

23. Giovannucci E, Liu Y, Rimm EB, et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst. 2006;98:451-459.

24. Lim U, Freedman DM, Hollis BW, et al. A prospective investigation of serum 25-hydroxyvitamin D and risk of lymphoid cancers. Int J Cancer. 2009;124:979-986.

25. Li YY, Jiang WQ, Huang J, Xia ZJ, Huang HQ, Li ZM. The Glasgow Prognostic Score (GPS) as a novel and significant predictor of extranodal natural killer/T-cell lymphoma, nasal type. Am J Hematol. 2013;88:394-399.

26. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331:1565-1570.

27. Scrolletta S, Colletti M, Di Luigi L, Crescioli C. Vitamin D receptor agonists target CXCL10: new therapeutic tools for resolution of inflammation. Mediators Inflamm. 2013;2013:876319.

28. Wobke TK, Sorg BL, Steinhilber D. Vitamin D in inflammatory diseases. Front Physiol. 2014;5:244.

29. Olliver M, Spelmink L, Hiew J, Meyer-Hoffert U, Henriques-Normark B, Bergman P. Immunomodulatory effects of vitamin D on innate and adaptive immune responses to Streptococcus pneumoniae. J Infect Dis. 2013;208:1474-1481.

30. Koyama S, Fujisawa S, Watanabe R, et al. Serum ferritin level is a prognostic marker in patients with peripheral T-cell lymphoma. Int J Lab Hematol. 2017;39:112-117.

31. Vose J, Armitage J, Weisenburger D, International TCLP. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124-4130.

32. Sfeir JG, Drake MT, LaPlant BR, et al. Validation of a vitamin D replacement strategy in vitamin D-insufficient patients with lymphoma or chronic lymphocytic leukemia. Blood Cancer J. 2017;7:e526.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Kim SJ, Shu C, Ryu KJ, et al. Vitamin D deficiency is associated with inferior survival of patients with extranodal natural killer/T-cell lymphoma. Cancer Sci. 2018;109:3971–3980. https://doi.org/10.1111/cas.13844